Gå direkt till innehåll

Senaste nyheterna

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment


Press release

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment
CAMBRIDGE, UK; GOTHENBURG, Sweden – 29 November 2023 – Camallergy, a pioneer in developing oral immunotherapy treatments for food allergies, and OnDosis, a leader in intelligent dosing of oral solid medicines, are excited to announce a strategic collaboration.
This

Kontakter

Martin Olovsson

Martin Olovsson

Presskontakt CEO Ondosis +46 76-772 85 01

OnDosis – Changing the game, one dose at a time

Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.

OnDosis AB

Pepparedsleden 1
431 50 Mölndal
Sweden